Ding Wang

5.8k citations

134 papers · 3.6k indexed · 2 hit papers · h-index 28

Impact in

Oncology top 1%
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Lung Cancer Research Studies
Immunology top 5%
- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction

Papers in ⓘ

Oncology 52
- Cancer Immunotherapy and Biomarkers 27
- Lung Cancer Research Studies 9
- Colorectal Cancer Treatments and Studies 7
Cancer Research 21
- MicroRNA in disease regulation 9

Co-authors: James L. Gulley (13 shared papers)Manish R. Patel (14 shared papers)Jeffrey R. Infante (11 shared papers)Andrea B. Apolo (8 shared papers)Alain Ravaud (8 shared papers)Karen Kelly (14 shared papers)Carolyn D. Britten (7 shared papers)Arnold B. Gelb (4 shared papers)
Journals: Journal of Clinical Oncology (29 papers)Blood (4 papers)Journal for ImmunoTherapy of Cancer (3 papers)Journal of Molecular and Cellular Cardiology (2 papers)The Lancet Oncology (2 papers)
Partner nations: United States China France

In The Last Decade

Ding Wang

122 papers receiving 3.5k citations

Hit Papers

align trajectories log scale

Avelumab, an Anti–Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study 2017 · 466 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2017 Journal of Clinical Oncology
2017 The Lancet Oncology

Peers

Countries citing papers authored by Ding Wang

Since Specialization

Citations

This map shows the geographic impact of Ding Wang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ding Wang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ding Wang more than expected).

Fields of papers citing papers by Ding Wang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ding Wang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ding Wang. The network helps show where Ding Wang may publish in the future.

Co-authors

The 25 scholars most cited alongside Ding Wang, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Ding Wang Line = papers co-authored together Ding Wang links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 134 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Avelumab, an Anti–Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study Journal of Clinical Oncology ·Andrea B. Apolo, Jeffrey R. Infante, Ani Sarkis Balmanoukian, Manish R. Patel, Ding Wang, Karen Kelly, Anthony Mega, Carolyn D. Britten, Alain Ravaud, Alain C. Mita, Howard Safran, Thomas E. Stinchcombe, Marko Srdanov, Arnold B. Gelb, Michael Schlichting, Kevin M. Chin, James L. Gulley Hit paper breakdown →	2017	466
2	Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial The Lancet Oncology ·Manish R. Patel, John Ellerton, Jeffrey R. Infante, Manish Agrawal, Michael S. Gordon, Raid Aljumaily, Carolyn D. Britten, Luc Dirix, Keun‐Wook Lee, Mathew Taylor, Patrick Schöffski, Ding Wang, Alain Ravaud, Arnold B. Gelb, Junyuan Xiong, Galit Rosen, James L. Gulley, Andrea B. Apolo Hit paper breakdown →	2017	429
3	Induction of Antigen-Specific Immunity with a Vaccine Targeting NY-ESO-1 to the Dendritic Cell Receptor DEC-205 Science Translational Medicine ·Madhav V. Dhodapkar, Mario Sznol, Biwei Zhao, Ding Wang, Richard D. Carvajal, Mary Louise Keohan, Ellen Chuang, Rachel E. Sanborn, Jose Lutzky, John D. Powderly, Harriet M. Kluger, Sheela Tejwani, Jennifer Green, Venky Ramakrishna, Andrea Crocker, Laura Vitale, Michael Yellin, Thomas A. Davis, Tibor Keler	2014	305
4	Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial The Lancet Oncology ·James L. Gulley, Arun Rajan, David R. Spigel, Nicholas Iannotti, Jason C. Chandler, Deborah Jean Lee Wong, Joseph W. Leach, W. Jeff Edenfield, Ding Wang, H. Grote, Anja von Heydebreck, Kevin M. Chin, Jean-Marie Cuillerot, Karen Kelly	2017	225
5	Human umbilical cord mesenchymal stem cells hUC-MSCs exert immunosuppressive activities through a PGE2-dependent mechanism Clinical Immunology ·Ke Chen, Ding Wang, Wei Du, Zhibo Han, He Ren, Ying Chi, Shao Guang Yang, Delin Zhu, Françis Bayard, Zhongchao Han	2010	159
6	A Phase II Trial of Fosbretabulin in Advanced Anaplastic Thyroid Carcinoma and Correlation of Baseline Serum-Soluble Intracellular Adhesion Molecule-1 with Outcome Thyroid ·Colin Mooney, Govardhanan Nagaiah, Pingfu Fu, Jay Wasman, Matthew M. Cooney, P. Savvides, Joseph A. Bokar, Afshin Dowlati, Ding Wang, Sanjiv S. Agarwala, Susan M. Flick, Paul Hartman, José Ortiz, Pierre Lavertu, Scot C. Remick	2009	153
7	Functional Dissection of a Neuronal Network Required for Cuticle Tanning and Wing Expansion inDrosophila Journal of Neuroscience ·Haojiang Luan, William C. Lemon, Nathan C. Peabody, Jascha B. Pohl, Paul K. Zelensky, Ding Wang, Michael N. Nitabach, Todd C. Holmes, Benjamin H. White	2006	148
8	Avelumab (MSB0010718C), an anti-PD-L1 antibody, in advanced NSCLC patients: A phase 1b, open-label expansion trial in patients progressing after platinum-based chemotherapy. Journal of Clinical Oncology ·James L. Gulley, David R. Spigel, Karen Kelly, Jason C. Chandler, Arun Rajan, Raffit Hassan, Deborah Jean Lee Wong, Joseph L. Leach, William J. Edenfield, Ding Wang, Nandagopal Vrindavanam, Glen J. Weiss, Jayne S. Gurtler, H. Grote, Anja von Heydebreck, Kevin M. Chin, Nicholas Iannotti	2015	71
9	Enhanced Keap1-Nrf2 signaling protects the myocardium from isoproterenol-induced pathological remodeling in mice Redox Biology ·Gobinath Shanmugam, Anil K. Challa, Silvio Litovsky, Asokan Devarajan, Ding Wang, Dean P. Jones, Victor Darley‐Usmar, Namakkal S. Rajasekaran	2019	68
10	Avelumab as second-line therapy for metastatic, platinum-treated urothelial carcinoma in the phase Ib JAVELIN Solid Tumor study: 2-year updated efficacy and safety analysis Journal for ImmunoTherapy of Cancer ·Andrea B. Apolo, John Ellerton, Jeffrey R. Infante, Manish Agrawal, Michael S. Gordon, Raid Aljumaily, Theodore Stewart Gourdin, Luc Dirix, Keunwook Lee, Matthew H. Taylor, Patrick Schöffski, Ding Wang, Alain Ravaud, Juliane Manitz, Gregory Pennock, Mary Ruisi, James L. Gulley, Manish R. Patel	2020	60
11	Tandem Mass Spectrometry for the Direct Assay of Enzymes in Dried Blood Spots: Application to Newborn Screening for Mucopolysaccharidosis II (Hunter Disease) Clinical Chemistry ·Ding Wang, Tim Wood, Martin Sadı́lek, C. Ronald Scott, František Tureček, Michael H. Gelb	2006	58
12	Sotatercept (ACE-011) for the treatment of chemotherapy-induced anemia in patients with metastatic breast cancer or advanced or metastatic solid tumors treated with platinum-based chemotherapeutic regimens: results from two phase 2 studies Supportive Care in Cancer ·H. Raftopoulos, Abderrahmane Laadem, Paul J. Hesketh, Jerome H. Goldschmidt, Nashat Gabrail, Cynthia R. Osborne, Muhammad Ali, Matthew L. Sherman, Ding Wang, John A. Glaspy, Marie Puccio-Pick, Jun Zou, Jeffrey Crawford	2015	57
13	A phase I study of mRNA-2752, a lipid nanoparticle encapsulating mRNAs encoding human OX40L, IL-23, and IL-36γ, for intratumoral (iTu) injection alone and in combination with durvalumab. Journal of Clinical Oncology ·Manish R. Patel, Todd M. Bauer, Antonio Jimeno, Ding Wang, Patricia LoRusso, Khanh Tu, Salomon M. Stemmer, Corinne Maurice‐Dror, Ravit Geva, Sima J. Zacharek, Andressa S. Laino, Jing Sun, Joshua P. Frederick, Haiyu Zhou, William Randolph, Pamela Cohen, Robert Meehan, Ryan J. Sullivan	2020	57
14	Tandem Mass Spectrometric Analysis of Dried Blood Spots for Screening of Mucopolysaccharidosis I in Newborns Clinical Chemistry ·Ding Wang, Bhramara Eadala, Martin Sadı́lek, Néstor Chamoles, František Tureček, C. Ronald Scott, Michael H. Gelb	2005	48
15	Identification of Oxalic Acid and Tartaric Acid as Major Persistent Pain-inducing Toxins in the Stinging Hairs of the Nettle, Urtica thunbergiana Annals of Botany ·HAN YI FU, Shiang Jiuun Chen, Ruei‐Feng Chen, Ding Wang, LING LONG KUO-HUANG, Rong Huang	2006	47
16	Inhibition of Nonsense-Mediated RNA Decay Activates Autophagy Molecular and Cellular Biology ·Jordan Wengrod, Leenus Martin, Ding Wang, Pamela A. Frischmeyer‐Guerrerio, Harry C. Dietz, Lawrence B. Gardner	2013	47
17	A phase I safety and pharmacokinetic study of ABT-263 in combination with carboplatin/paclitaxel in the treatment of patients with solid tumors Investigational New Drugs ·Gordana Vlahovic, Vassiliki Karantza, Ding Wang, David Cosgrove, Nikita Rudersdorf, Jianning Yang, Hao Xiong, Todd Busman, Mack Mabry	2014	46
18	A phase Ib study of utomilumab (PF-05082566) in combination with mogamulizumab in patients with advanced solid tumors Journal for ImmunoTherapy of Cancer ·Ezra E.W. Cohen, Michael J. Pishvaian, Dale R. Shepard, Ding Wang, Jared Weiss, Melissa L. Johnson, Christine H. Chung, Ying Chen, Bo Huang, Craig B. Davis, Francesca Toffalorio, Aron D. Thall, Steven Powell	2019	45
19	Clinical Evaluation and Therapeutic Monitoring Value of Serum Tumor Markers in Lung Cancer The International Journal of Biological Markers ·Lishui Wang, Ding Wang, Guixi Zheng, Yongmei Yang, Lutao Du, Zhaogang Dong, Xin Zhang, Chuanxin Wang	2015	41
20	Metabolic lactate production coordinates vasculature development and progenitor behavior in the developing mouse neocortex Nature Neuroscience ·Xiaoxiang Dong, Qiangqiang Zhang, Xiangyu Yu, Ding Wang, Jiaming Ma, Jian Ma, Song‐Hai Shi	2022	39

About Ding Wang

Ding Wang is a scholar working on Oncology, Cancer Research, Genetics, Pulmonary and Respiratory Medicine and Immunology, having authored 134 papers that have together received 3.6k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (27 papers), Lung Cancer Treatments and Mutations (12 papers), Bladder and Urothelial Cancer Treatments (10 papers), Lung Cancer Research Studies (9 papers), MicroRNA in disease regulation (9 papers), Urinary and Genital Oncology Studies (8 papers), Immune Cell Function and Interaction (7 papers) and Colorectal Cancer Treatments and Studies (7 papers). The work is most often cited by research in Oncology (1.8k citations), Immunology (889 citations), Genetics (284 citations), Surgery (898 citations) and Cancer Research (293 citations). Ding Wang has collaborated with scholars based in United States, China and France. Frequent co-authors include James L. Gulley, Manish R. Patel, Jeffrey R. Infante, Andrea B. Apolo, Alain Ravaud, Karen Kelly, Carolyn D. Britten, Arnold B. Gelb, Kevin M. Chin and Alain C. Mita. Their work appears in journals such as Journal of Clinical Oncology, Blood, Journal for ImmunoTherapy of Cancer, Journal of Molecular and Cellular Cardiology and The Lancet Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact